# Milestone Scientific Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [Milestone Scientific Inc.](/companies/mlss.md) (CIK 855683)
- Form: 10-Q
- Filed: 2018-11-14
- Accepted by EDGAR: Nov 14, 2018, 16:07 ET
- Period: 2018-09-30
- Accession: 0001437749-18-020817
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/855683/000143774918020817/mlss20180930_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/855683/000143774918020817/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $1.6m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $5.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $1.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $3.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2018-07-01 to 2018-09-30 | −$120.2k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-01-01 to 2018-09-30 | $2.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2018-07-01 to 2018-09-30 | $1.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2018-01-01 to 2018-09-30 | $215.7k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2018-07-01 to 2018-09-30 | $2.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2018-01-01 to 2018-09-30 | $8.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | −$4.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | −$8.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2018-07-01 to 2018-09-30 | $1.6k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-01-01 to 2018-09-30 | $17.2k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | −$4.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | −$7.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | −$0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-01-01 to 2018-09-30 | −$0.22 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-07-01 to 2018-09-30 | 35,586,995 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-01-01 to 2018-09-30 | 35,086,822 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | −$2.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $6.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2018-09-30 | $414.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $7.1m | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $7.6m | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $6.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $6.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2018-09-30 | $915.6k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 29,245 characters.

The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this annual report. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements.

### OVERVIEW

Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and devices for medical, dental, cosmetic and veterinary applications. Since our inception, we have engaged in pioneering proprietary, innovative, computer-controlled injection technologies and solutions for the medical and dental markets. We have focused our resources on redefining the worldwide standard of care for injection techniques by making the experience more comfortable for the patient by reducing the anxiety and stress of receiving injections from the healthcare provider. Our computer-controlled injection systems make injections precise, efficient and virtually painless. Milestone’s proprietary *DPS* Dynamic Pressure Sensing technology is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.

Milestone Scientific remains focused on advancing efforts to achieve the following five primary objectives:

- Establishing Milestone’s DPS Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first-time objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications;
- Following successful FDA clearance of our first medical device in June 2017, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company;
- Commercializing our *CompuFlo* Epidural System, a transformative device for epidural anesthesia procedures;
- Expanding the global footprint of our CompuFlo Epidural System by partnering with distribution companies worldwide; and
- Obtaining regulatory approval of our proprietary cosmetic injection device for delivery of botulinum toxin (such as Botox® and Dysport®) and subsequent commercial launch.

### Distribution and Marketing Arrangements

Our dental devices are sold in the United States, Canada, and in 53 other countries. In June 2017, we received FDA regulatory clearance to sell our first medical device, the *CompuFlo* Epidural System in the United States. Since receiving FDA clearance in 2017 our epidural devices have had minimal sales in the United States and Europe.

### Dental Market

In the spring of 2009, Milestone Scientific signed a distribution and marketing agreement with China National Medicines Corporation, dba Sinopharm. In early October 2012, the State Food and Drug Administration (“CFDA”) of the People’s Republic of China approved the *Wand STA* System. However, the CFDA’s approval of the Wand STA handpieces was not received until May 2014 and the distribution of these handpieces in China began in the fourth quarter of 2014. The distribution and marketing agreement with Sinopharm were terminated in September 2014. Proximate to that time, we entered into a new agreement with Milestone China to be our distributor for the *Wand STA* System and handpieces in China.

In November 2012, Milestone Scientific signed an exclusive distributor and marketing agreement with a well-known U.S. domestic manufacturer and distributor, for the sale and distribution of the *Wand STA* System and handpieces in the United States and Canada. The marketing initiative included participation in United States and Canadian dental shows, as well as pediatric dental shows; an active advertising initiative targeting major dental publications; and direct mailing campaigns to over 150,000 dentists across the United States and Canada. This exclusive distributor and marketing agreement was converted to a non-exclusive agreement as of December 31, 2016.

Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein. In June 2016, that agreement was replaced by a new agreement with Henry Schein providing for an exclusive distribution arrangement for our dental products in the United States and Canada by a newly formed marketing and sales group at Henry Schein. Under this arrangement, we have a semi-dedicated independent sales force visiting dentists. Henry Schein’s exclusive products sales specialist team, which is comprised of 25 sales representatives and supported by over 1,000 field service representatives, will exclusively market and distribute the *Wand STA* System and handpieces, together with a select group of other devices in the United States and Canada. Our agreement with Henry Schein has minimum purchase orders to maintain exclusivity in the third through tenth years. We believe that this exclusive arrangement will be more effective than previous arrangements relying on Wand Dental's appearances at dental shows and catalog sales.

### Medical Market

Having received FDA clearance to sell the *CompuFlo* Epidural System in June 2017, we are in discussions with, and have entered into a small number of agreements with, regional and national distributors. Our immediate focus is on marketing our epidural device in the U.S. and throughout Europe.

In February and March 2018, Milestone Scientific hired an Executive VP of Global Sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the *CompuFlo* Epidural System.

In October 2018, Milestone Scientific signed its first USA Stocking Distributor Agreement for the CompuFlo Epidural device. This distributor purchases devices and disposables subsequent to signing the agreement.

We have entered into a limited number of distributor arrangements in Europe and the Middle East for our CompuFlo Epidural Computer Controlled Anesthesia System. Our distribution strategy is initially aimed at having Key Opinion Leaders (KOL) use and accept the device and initiate their own studies. This having been accomplished we are now placing devices in key institutions.

The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category for three months ended September 30, 2018 and 2017:

| Domestic US / Canada: | Three months ended September 30, 2018 Dental | Medical | Total | Three months ended September 30, 2017 Dental | Medical | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Device | $119,190 | $- | $119,190 | $452,232 | $- | $452,232 |
| Handpieces | 369,027 | - | 369,027 | 893,496 | - | 893,496 |
| Other | 21,037 | - | 21,037 | 12,338 | - | 12,338 |
| Total Domestic US / Canada | $509,254 | $- | $509,254 | $1,358,066 | $- | $1,358,066 |
| International Rest of the World: |  |  |  |  |  |  |
| Device | $299,872 | $- | $299,872 | $340,575 | $- | $340,575 |
| Handpieces | 506,880 | - | 506,880 | 765,821 | - | 765,821 |
| Other | 6,240 | - | 6,240 | 32,951 | - | 32,951 |
| Total International Rest of the World | $812,992 | $- | $812,992 | $1,139,347 | $- | $1,139,347 |
| International China: |  |  |  |  |  |  |
| Device | $- | $- | $- | $- | $- | $- |
| Handpieces | 300,000 | - | 300,000 | 356,400 | - | 356,400 |
| Other | - | - | - | - | - | - |
| Total International China | $300,000 | $- | $300,000 | $356,400 | $- | $356,400 |
| Total Product Sales | $1,622,246 | $- | $1,622,246 | $2,853,813 | $- | $2,853,813 |

21

The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category for the nine months ended September 30, 2018 and 2017:

| Domestic US / Canada: | Nine months ended September 30, 2018 Dental | Medical | Total | Nine months ended September 30, 2017 Dental | Medical | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Device | $251,743 | $- | $251,743 | $857,525 | $- | $857,525 |
| Handpieces | 2,296,533 | - | 2,296,533 | 3,230,567 | - | 3,230,567 |
| Other | 72,265 | - | 72,265 | 53,037 | - | 53,037 |
| Total Domestic US / Canada | $2,620,541 | $- | $2,620,541 | $4,141,129 | $- | $4,141,129 |
| International Rest of the World: |  |  |  |  |  |  |
| Device | $876,290 | $70,500 | $946,790 | $1,053,050 | $- | 1,053,050 |
| Handpieces | 1,924,901 | 5,600 | 1,930,501 | 2,068,007 | - | 2,068,007 |
| Other | 58,519 | - | 58,519 | 89,764 | - | 89,764 |
| Total International Rest of the World | $2,859,710 | $76,100 | $2,935,810 | $3,210,821 | $- | $3,210,821 |
| International China: |  |  |  |  |  |  |
| Device | $- | $- | $- | $1,000,000 | $- | $1,000,000 |
| Handpieces | 300,000 | - | 300,000 | 712,800 | - | 712,800 |
| Other | - | - | - | 1,800 | - | 1,800 |
| Total International China | $300,000 | $- | $300,000 | $1,714,600 | $- | $1,714,600 |
| Total Product Sales | $5,780,251 | $76,100 | $5,856,351 | $9,066,550 | $- | $9,066,550 |

Milestone Scientific plans to support increased sales and marketing activity through our current distributors and through newly appointed distributors of the Wand STA devices and handpieces in the international market. In the United States and Canada, Milestone Scientific will continue the utilization of independent hygienists for training individual practitioners and group practices domestically, refined and directed advertising to dental professionals, continue to develop Key Opinion Leaders (KOL) and support and broaden our global distribution network. Additionally, with the FDA marketing clearance for the *CompuFlo* Epidural System, Milestone Scientific is initiating marketing and sales efforts in the U.S. to establish medical sector distributors for the sale of this device.

### Current Product Platform

See Item 1. Description of Business.

### Results of Operations

The following table sets forth for the consolidated results of operations for the three months ended September 30, 2018 compared to 2017 as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results:

| Operating results: | Three Months Ended September 30, 2018 |  | 2017 |  |
| --- | ---: | ---: | ---: | ---: |
| Product sales, net | $1,622,246 | 100% | $2,853,813 | 100% |
| Cost of products sold | 1,742,451 | 107% | 1,044,540 | 37% |
| Gross profit (loss) | (120,205) | -7% | 1,809,273 | 63% |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative expenses | 2,886,081 | 178% | 3,205,996 | 112% |
| Research and development expenses | 1,500 | 0% | 16,884 | 1% |
| Impairment of long lived assets | 1,539,794 | 95% | - | 0% |
| Loss from operations | (4,547,580) | -280% | (1,413,607) | -50% |
| Other income, net | 143,015 | 9% | (3,939) | 0% |
| Net loss | (4,404,565) | -272% | (1,417,546) | -50% |
| Net loss attributable to noncontrolling interests | 11,742 | 1% | 6,605 | 0% |
| Net loss attributable to Milestone Scientific Inc. | $(4,392,823) | -271% | $(1,410,941) | -49% |

22

The following table sets forth for the consolidated results of operations for the nine months ended September 30, 2018 compared to 2017 as a percentage of product sales, net. The trends suggested by this table may not be indicative of future operating results:

| Operating results: | Nine Months Ended September 30, 2018 |  | 2017 |  |
| --- | ---: | ---: | ---: | ---: |
| Product sales, net | $5,856,351 | 100% | $9,066,550 | 100% |
| Cost of products sold | 3,326,341 | 57% | 3,320,411 | 37% |
| Gross profit | 2,530,010 | 43% | 5,746,139 | 63% |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative expenses | 8,748,485 | 149% | 8,996,092 | 99% |
| Research and development expenses | 215,655 | 4% | 241,964 | 3% |
| Impairment of long lived assets | 1,539,794 | 26% | - | 0% |
| Loss from operations | (7,973,924) | -136% | (3,491,917) | -39% |
| Other income, net | 243,987 | 4% | (44,063) | 0% |
| Net loss | (7,729,937) | -132% | (3,535,980) | -39% |
| Net loss attributable to noncontrolling interests | 118,424 | 2% | 138,915 | 2% |
| Net loss attributable to Milestone Scientific Inc. | $(7,611,513) | -130% | $(3,397,065) | -37% |

| Cash flow: | September 30, 2018 | September 30, 2017 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(1,957,602) | $(1,560,152) |
| Net cash used in investing activities | (14,525) | (197,916) |
| Net cash provided by financing activities | (250,000) | 463,366 |

### Three Months Ended September 30, 2018 compared to Three Months Ended September 30, 2017

### Net sales for three months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $1,622,248 | $2,853,813 | $(1,231,565) | -43.16% |
| Medical | - | - | - | - |
| Total sales, net | $1,622,248 | $2,853,813 | $(1,231,565) | -43.16% |

Consolidated revenue for the three months ended September 30, 2018 and 2017 were approximately $1.6 million and $2.8 million, respectively. Dental revenue decreased approximately $1.2 million during the three months ended September 2018 compared to 2017. This decrease was primarily related to a decrease of approximately $848,000 related to a delay in the quarterly re-stocking order for handpieces and devices from Henry Schein. The third quarter re-stocking order was received and shipped in October 2018 in the amount $773,000. International dental revenue decreased approximately $326,000 for the three months ended September 2018 compared to 2017. China revenue decreased for three months ended September 30, 2018 by approximately $56,000 compared to 2017, as for the quarter ending September 30, 2018, the Company recognized $300,000 in revenue previously deferred until payment was received by Milestone Scientific.

### Gross profit for three months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $(120,205) | $1,809,273 | $(1,929,478) | -106.64% |
| Medical | - | - | - | 0.00% |
| Total gross profit | $(120,205) | $1,809,273 | $(1,929,478) | -106.64% |

Consolidated gross profit for the three months ended September 30, 2018 included a reserve of approximately $273,000 for certain dental handpieces. A claim has been made for reimbursement of this purchase to the broker and manufacture that provided the handpieces to the Company. The gross profit percentages for three months ended September 30, 2018 and 2017 were approximately -7% and 63%, respectively. For the three months ended September 30, 2018, the Company recorded an allowance for handpieces and devices sold to Milestone China of approximately $790,000.

### Selling, general and administrative expenses for three months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $772,943 | $1,097,684 | $(324,741) | -29.58% |
| Medical | 454,306 | 501,054 | (46,748) | -9.33% |
| Corporate | 1,658,832 | 1,607,258 | 51,574 | 3.21% |
| Total selling, general and administrative expenses | $2,886,081 | $3,205,996 | $(319,915) | -9.98% |

Consolidated selling, general and administrative expenses for the three months ended September 30, 2018 and 2017 were $2.8 million and $3.2 million, respectively. The decrease of approximately $320,000 is primarily related to an decrease compensation, marketing and professional fees of approximately $373,000 offset by a decrease in general expense, and employee related expenses of approximately $53,000 for the three months ending September 30, 2018.

Additionally, during the quarter Milestone Scientific charged approximately $1.5 million to the Corporate segment for an impairment of long-lived assets (Apad patents).

### Research and Development for three months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $- | $- | $- | 0.00% |
| Medical | - | 16,884 | (16,884) | -100.00% |
| Corporate | 1,500 | - | 1,500 | 100.00% |
| Total research and development | $1,500 | $16,884 | $(15,384) | -91.12% |

Consolidated research and development expenses for the three months ended September 30, 2018 and 2017 were approximately $1,500 and $17,000, respectively. The decrease is due to a delay in the development of the cosmetic injection device during the second quarter of 2018.

### Loss from Operations for three months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $(893,148) | $711,589 | $(1,604,737) | -225.51% |
| Medical | (454,306) | (517,938) | 63,632 | 12.29% |
| Corporate | (3,200,126) | (1,607,258) | (1,592,868) | -99.10% |
| Total loss from operations | $(4,547,580) | $(1,413,607) | $(3,133,973) | -221.70% |

The loss from operations for the three months ended September 30, 2018 and 2017 was approximately $4.5 million and $1.4 million, respectively, an increase of approximately $3.1 million. As noted above, third quarter sales decreased by approximately $1.2 million and gross profit by approximately $1.9 million offset by a reduction of approximately $320,000 in selling, general and administrative expenses and increase of approximately $1.5 million for the write-down of long- lived assets(Apad Patents) accounted for the loss from operations for the three months ending September 30, 2018. The dental segment of the business continues to control expenses for a stable market. Costs in the medical segment are increasing as personnel are expanded in the U.S. to focus on our domestic Epidural device business.

### Nine months ended September 30, 2018 compared to nine months ended September 30, 2017

### Net sales for nine months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $5,780,251 | $9,066,550 | $(3,286,299) | -36.25% |
| Medical | 76,100 | - | 76,100 | 100.00% |
| Total sales, net | $5,856,351 | $9,066,550 | $(3,210,199) | -35.41% |

Consolidated net sales for the nine months ended September 30, 2018 and 2017 were approximately $5.8 million and $9.1 million, respectively. Dental revenue for the nine months ended September 30, 2018 and 2017 were $5.7 million and $9.1 million, respectively. Dental revenue decreased $3.2 million during the nine months ended September 30, 2018, compared to 2017.

The domestic dental revenue decrease of approximately $1.5 million is related to a delay in the quarterly re-stocking order for handpieces and devices from Henry Schein and their focus on working through the inventory purchased in the fourth quarter of 2017. The third quarter re-stocking order was received and shipped in October 2018 in the amount of $773,000. Henry Schein's inventory of handpieces was less than a half month supply as of September 30, 2018. The receipt of the re-stocking order post-September 30 resulted in out stock positioning for Henry Schein’s customers in October 2018 until the order was shipped. International dental revenue excluding China decreased by approximately $350,000 for the nine months ended September 2018 compared to 2017. China revenue decreased for nine months ended September 30, 2018 by approximately $1.4 million compared to 2017, as the Company recognized $300,000 in revenue previously deferred until payment was received by Milestone Scientific. Milestone China is working through inventory purchases from 2017 and making modifications to their business strategy to better serve the Chinese dental market.

### Gross Profit (loss) for nine months ended September 30, 2018 and 2017 were as follows

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $2,710,882 | $5,746,139 | $(3,035,257) | -52.82% |
| Medical | (180,872) | - | (180,872) | -100.00% |
| Total gross profit | $2,530,010 | $5,746,139 | $(3,216,129) | -55.97% |

Consolidated gross profit for the nine months ended September 30, 2018 and 2017 were approximately 43% and 63% respectively. The gross profit dollars in 2018 decreased to $2.5 million from $5.7 million in 2017, or by $3.2 million over the same period year over year. The gross profit dollars decrease relates to a decrease of approximately $3.2 million in revenue, reserve for slow moving inventory of approximately $289,000 and a reserve of approximately $273,000 for certain dental handpieces. A claim has been made for reimbursement of this purchase to the broker and manufacture that provided the handpieces to the Company. For the three months ended September 30, 2018, the company recorded an allowance for handpieces and devices sold to Milestone China of approximately $790,000.

### Selling, general and administrative expenses for nine months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $2,591,269 | $3,195,540 | $(604,271) | -18.91% |
| Medical | 1,762,972 | 1,629,598 | 133,374 | 8.18% |
| Corporate | 4,394,244 | 4,170,954 | 223,290 | 5.35% |
| Total selling, general and administrative expenses | $8,748,485 | $8,996,092 | $(247,607) | -2.75% |

Consolidated selling, general and administrative expenses for the nine months ended September 30, 2018 and 2017 were approximately $8.7 million and $9.0 million respectively. The decrease of approximately $247,000 is primarily related to an decrease in compensation, marketing and professional fees of approximately $653,000 and a decrease in general expense, and employee related expenses of approximately $406,000 for the three months ending September 30, 2018.

Additionally, during the quarter Milestone Scientific charged approximately $1.5 million to the Corporate segment for an impairment of long-lived assets (Apad patents).

### Research and Development for nine months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $- | $3,000 | $(3,000) | -100.00% |
| Medical | 65,008 | 116,793 | (51,785) | -44.34% |
| Corporate | 150,647 | 122,171 | 28,476 | 23.31% |
| Total research and development | $215,655 | $241,964 | $(26,309) | -10.87% |

Consolidated research and development expenses for the nine months ended September 30, 2018 and 2017 were approximately $215,000 and $241,000, respectively. The decrease is due a delay in the development of the cosmetic

injection device during the second and third quarter of 2018.

### Profit (Loss) from Operations for nine months ended September 30, 2018 and 2017 were as follows:

|  | 2018 | 2017 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $119,613 | $2,547,599 | $(2,427,986) | -95.30% |
| Medical | (2,008,852) | (1,746,391) | (262,461) | -15.03% |
| Corporate | (6,084,685) | (4,293,125) | (1,791,560) | -41.73% |
| Total loss from operations | $(7,973,924) | $(3,491,917) | $(4,482,007) | -128.35% |

The loss from operations for the nine months ended September 30, 2018 and 2017 was approximately $8 million and $3.5 million, respectively, an increase of approximately $4.5 million. As noted above, sales and gross profit decreased by approximately $3.2 million for the nine months ending September 30, 2018. The decrease in gross profit is related to a reserve for slow moving inventory of approximately $289,000 and a reserve of approximately $273,000 for certain dental handpieces. A claim has been made for reimbursement of this purchase to the broker and manufacture that provided the handpieces to the Company. For the nine months ended September 30, 2018, the Company recorded an allowance for handpieces and devices sold to Milestone China of approximately $790,000.

Additionally, during the quarter Milestone Scientific charged approximately $1.5 million to the Corporate segment for an impairment of long-lived assets (Apad patents). The dental segment of the business continues to control expenses for a stable market. Costs in the medical segment are increasing as personnel are expanded in the U.S. to focus on our domestic Epidural device business.

### Liquidity and Capital Resources

At September 30, 2018, Milestone Scientific had cash and cash equivalents of $0.4 million, total current assets of approximately $7 million and working capital of approximately $0.5 million. Based on the delayed payment for shipments made to Milestone China in 2017 and 2018, substantial doubt exists about the company’s liquidity and ability to continue as a going concern as of September 30, 2018.

Management as of September 30, 2018, believes that without the collection of the Milestone China Accounts Receivable (a reserve for non-collectability was established of approximately $1.3 million), and provided that the Company's sales performance, selling expenditures for its Epidural medical device, and the new product development programs deviate from management’s plan, the Company will not be able to meet its anticipated obligations over the next twelve months from the financial reporting date. Significant deviations, together with limitations on funding could require a delay, scale back or elimination of some or all of the Company’s development programs which could have a material adverse impact on the Company.

Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception. The capital raised in December 2016 and January 2017 provided Milestone Scientific with working capital to continue to develop its medical devices and obtain FDA regulatory clearance of its *CompuFlo* Epidural System, as well as to market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide and a reduction in operating expenses.

Now that the *CompuFlo* Epidural System has obtained FDA clearance in the United States, the Company’s development costs should be lower in 2018. The FDA clearance will provide the Company with the opportunity to establish distribution in the U.S. At the same time, the Company is looking to establish additional financing opportunities to help with the commercialization of the Epidural device. In June 2018, Milestone Scientific filed a new 510(k) application for its intra-articular device. Most of the cost associated with this application were internal personnel cost and some low level third party review expense.

Milestone Scientific believes that the FDA clearance of its 510(k) applications with respect to the *CompuFlo* Epidural System will provide Milestone Scientific with the opportunity to enter the US medical device market and generate revenues in the future. Milestone Scientific believes that it has sufficient inventory of epidural devices to satisfy the near-term marketing opportunities.

In February and March 2018 Milestone Scientific hired an Executive VP of Global sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the *CompuFlo* Epidural System.

Milestone Scientific believes that the exclusive distribution agreement with Henry Schein will continue to improve its domestic revenues in 2018. To further reduce Milestone Scientific's expenditures, Milestone Medical is carefully managing expenses related to obtaining FDA clearance for the intra-articular devices.

Our condensed consolidated balance sheets included in this Quarterly Report reflect a decrease of approximately $4.9 million in current assets from December 31, 2017 to September 30, 2018. This decrease in current assets was primarily due to a reduction in cash, accounts receivable related party (due to a reserve for doubtful accounts), notes receivable, inventory (reserve for production problems with a dental accessory) and a charge for Impairment on the APAD patents (approximately $1.5 million), in the aggregate of approximately $5.1 million. This was partially offset by increases in and advances on contracts of approximately $.2 million.

In this Quarterly Report our consolidated balance sheets included a decrease in current liabilities of approximately $150,000 from approximately $6.7 million to approximately $6.5 million. This decrease is primarily due to a decrease in accrued expenses, accrued expenses related party, deferred revenue and deferred profit related party of approximately $945,000 and an increase in accounts payable and accounts payable related party of approximately $796,000.

## Market risk

As filed, 162 characters.

Milestone Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information required by this item.

## Controls and procedures

As filed, 1,316 characters.

Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of September 30, 2018 are effective to ensure that information required to be disclosed in the reports Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Milestone Scientific's management, including the Interim Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. There have been no changes in Milestone Scientific’s internal control over financial reporting that occurred during Milestone Scientific’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific’s internal controls over financial reporting.

Filed Nov 14, 2018.
Source: SEC EDGAR, the filing index for accession 0001437749-18-020817. Last ingested by Listed: Nov 14, 2026, 11:14 ET. No prices; not investment advice.
